17α-estradiol is a hormonally inactive isomer of 17β-estradiol, but with similar potency as neuroprotector. However, we have previously reported that pretreatment with high concentration (10 µM) of both estrogens abolishes their neuroprotection in rat cerebellar granule neurons. Here, we have examined neuroprotective properties of 17α-estradiol against glutamate-induced excitotoxicity in chicken cerebellar granule neurons using low (1 nM) and high concentration.17α-Estradiol, 1 nM, was neuroprotective when glutamate was administered after a pretreatment period of 24 h, but not when coadministered with glutamate.
Introduction
It has long been accepted that estrogen has neuroprotective properties [1, 2] which may be mediated through estrogen receptors (ERs) [3, 4] , or through non-ER mechanisms [5] . Non-ER mechanisms have led to the development of non-feminizing estrogens that exert neuroprotection without activation of ERs [5, 6] . 17α-Estradiol is a stereoisomer of 17β-estradiol with >200 fold less estrogen activity, but with similar potency as a protector [7] .
However, we have previously reported that pretreatment with both 17β-estradiol and 17α-estradiol at high concentration (10 µM) abolishes their neuroprotection from glutamateinduced cell death in rat cerebellar granule neurons (CGNs) due to down-regulation of glutathione (GSH) [8] .
In stroke and neurodegenerative diseases, enhanced extracellular glutamate results in neurodegeneration and calcium dependent cell death in neurons [9] through N-methyl-ᴅ-aspartate (NMDA) receptors [10] . Further, production of nitric oxide (NO) is linked to NMDA receptor-mediated calcium influx through a structural link between the neuronal nitric oxide synthase (nNOS) and NMDA receptors [11] . NMDA receptors can have a synaptic or extrasynaptic localization. However, NMDA receptor stimulation is dramatically different between synaptic and extrasynaptic NMDA receptor as the extrasynaptic NMDA receptor is identified to mediate the excitotoxicity through excess levels of glutamate while synaptic NMDA receptors stimulation have anti-apoptotic activity [12] . NR2B subunit is found preferentially in extrasynaptic NMDA receptors and NR2A in the synaptic NMDA receptors [13] . Moreover, one of the mechanisms that 17β-estradiol protects neurons from glutamateinduced cell death is documented to be mediated through NMDA receptors [14, 15] . In addition, in micromolar concentrations, estrogen molecules work as reactive oxygen species (ROS) scavengers in glutamate-mediated neuronal toxicity due to its phenolic hydroxyl group [16] . The aim of the present study was therefore to investigate how 17α-estradiol works as a 4 neuroprotector against glutamate-induced toxicity in cultures of chicken CGNs using both high (10 µM) and low (1 nM) concentrations. We reveal that pretreatment with 1 nM of 17α-estradiol protects against glutamate-induced cell death, while pretreatment with 10 µM fails to protect. However, acute treatment with 17α-estradiol results in protection only at 10 µM, giving the molecule a concentration and time dependent protective effect against glutamateinduced cell death.
Material and methods

Materials
Basal Eagle's medium (BME) and L-glutamine were purchased from Lonza BioWhittaker (Verviers, Belgium). Penicillin-streptomycin (PenStrep) was acquired from Gibco, Life technologies (Paisley, UK). Chicken serum was obtained from Gibco and Biowest (Nuaillé, France). Dimethyl sulfoxide (DMSO), 17α-estradiol, dihydrorhodamine 123 (DHR), monochlorobimane (mBCl), cytosine β-D-arabinofuranoside (Ara-C), and anti-β-actin antibody were all obtained from Sigma-Aldrich (St. Lois, US). Anti-NMDAR2B antibody (ab65783) was purchased from Abcam (Cambridge, UK), donkey anti-rabbit horseradish peroxidase (HRP) conjugated secondary antibody was from Santa Cruz Biotechnology (Santa Cruz, US) and secondary antibody goat anti-mouse (HRP) was obtained from Bio-Rad (Hercules, California, US). Pierce ® BCA Protein Assay Kit was from Thermo Scientific (Rockford, US) while Luminata Crescendo/Forte was acquired from Merck Millipore (Temecula, US). Fura-2, AM was purchased from Invitrogen TM Molecular Probes (Eugene, US).
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Cell cultures and treatments
Eggs (Gallus gallus, 50-60 g) were obtained from Nortura Samvirkekylling (Våler, Norway) and incubated at 37.5° C in 45 % humidity in an OvaEasy 380 Advance EXII Incubator (Brinsea, Weston-super-Mare, UK). On embryonic day 17 eggs were anesthetized in crushed ice for 7 min before cultures of granule neurons were prepared from cerebella and isolated as previously described [17] . Cells were seeded out in BME supplemented with chicken serum (7.5%), KCl (25 mM), L-glutamine (2 mM), insulin (100 nM) and PenStrep (1%) with a density of 1.9 x 10 6 cells/mL in dishes or 96 wells plates. After 24 h medium was replaced with serum-free BME as previously described [18] supplemented with Ara-C (10 µM) to prevent growth of non-neuronal cells. For exposure treatments, DMSO (0.1%), 17α-estradiol
(1 nM or 10 µM), or DHR (0.1 µM) was used. After 4 days in vitro (DIV4) cultures were treated as in (i) or (ii). (i) Acute treatment, A: cultures were pre-incubated in physiological buffer described in [8] containing exposure treatments for 15 min. Then cultures were washed before exposed to 100 µM glutamate together with 10 µM glycine as coagonist in the absence or presence of exposure treatments in physiological buffer for 15 min. Cells serving as controls were untreated or treated with physiological buffer added 1.2 mM MgCl 2 . The glutamate exposure was removed and cultures were incubated in serum-free BME for 24 h.
(ii) Pretreatment, P: on DIV3 cultures were given exposure treatments. On DIV4, cultures were exposed to physiological buffer supplemented with glutamate as in (i). Control cells were treated as described in (i) for 15 min. Cell death was measured by trypan blue exclusion on DIV5 as described in [19] .
ROS measurements
CGNs were seeded out in black 96 wells plates and treated with DMSO or 17α-estradiol, or left untreated, on DIV3. On DIV4, cultures were loaded with DHR (0.1 µM) in the medium for 30 min (37° C). Then the cells were washed and glutamate exposed using experimental Total measurement in each well was at least 12 s and glutamate was injected after 2 s. First reading after injection was 2.6 s due to movement of the plate. Some wells were injected only with experimental buffer. Average of background autofluorescence in wells not loaded with Fura-2/AM were subtracted from excitations at 335 nm and 380 nm before 335/380 ratio in each well was used to calculate changes in intracellular calcium.
Western blot analysis
CGNs were unexposed or exposed to DMSO or 17α-estradiol on DIV3. After 24 h, the cultures were washed twice in ice cold PBS and harvested in 2% SDS with protease inhibitors 8 PMSF (300 µM), leupeptin (5 µg/ml), pepstatin A (1 µg/ml), and phosphatase inhibitor Na 3 VO 4 , (100 µM). Pierce ® BCA Protein Assay Kit was used to determine total protein concentration before proteins were analyzed with a standard western blot protocol described previously [19] using primary antibodies against NMDAR2B (1:1000) or β-actin (1:5000), and then with HRP conjugated secondary antibody (1:10 000). Immunoreactive protein was detected using a chemiluminescence gel documentation system (Syngene, Cambridge, UK)
with Luminata HRP detection substrates.
Statistical methods
Statistical analyses were performed in SigmaStat 3.5 software (Systat Software) and results are presented as mean ± SEM. Multiple comparisons were analyzed by one-way analysis of variance (ANOVA), followed by Dunnett's post hoc test. Kruskal-Wallis ANOVA on ranks followed by Dunn's post hoc test or Tukey test was applied on non-parametric data. Student's t-test was used for comparison between two groups. A p value of <0.05 was considered significant.
Results
We first investigated protection by 17α-estradiol against glutamate-induced cell death in chicken CGNs after 24 h (Figure 1 ). 17α-estradiol was either given 24 h prior to glutamate insult (pretreatment, P) or treated 15 minutes before and 15 minutes together with glutamate Since ROS is involved in the glutamate-induced cell death, neurons were pretreated or acutely treated with DHR ( Figure 2A) . Exposure with DHR resulted in a small reduction in glutamate-induced cell death, suggesting that ROS is involved to some extent. We further investigated peroxynitrite production at the time of glutamate exposure and after 1 h in cells pretreated or acutely treated with 17α-estradiol ( Figure 2B ). Glutamate caused a significant 2-fold increase in ROS production immediately during glutamate exposure and after 1 h.
Surprisingly, only cells pretreated with 10 µM of 17α-estradiol had significantly increased levels of ROS production 1 h after glutamate exposure. All the other treatments decreased the glutamate-induced ROS production.
Since reduction in GSH levels is involved in glutamate-induced cell death [8] , we investigated if this reduction also is seen in chicken CGNs. Glutamate exposure reduced the GSH levels after 24 h (Figure 3 ). Similar reduction was seen in cells pretreated with both concentrations of 17α-estradiol and given glutamate. In addition, a reduction was seen in cells that were only pretreated with 10 µM 17α-estradiol for 24 h. Pretreatment with 1 nM did not affect the GSH levels. Surprisingly, with acute treatment of both 1 nM and 10 µM of 17α-estradiol together with glutamate there was no reduction in the GSH level.
Glutamate-induced neurotoxicity is calcium dependent and changes in calcium levels during glutamate exposure were examined ( Figure 4A-F) . Injection of glutamate gave a rapid increase in intracellular calcium which lasted for at least 20 s ( Figure 4A ), while injection of buffer did not induce a response (data not shown). Pretreatment with 10 µM 17α-estradiol for 24 h also had a significant increase in calcium levels with glutamate exposure (Figure 4B and D), immediately after injection and after 10 s. However, pretreatment with 1 nM 17α-estradiol did not give a significant increase. Interestingly, when 17α-estradiol was present in the buffer (acute treatment), only 1 nM caused a significant glutamate-induced rise in calcium ( Figure   4C and D). Thus, significant increase in calcium levels with treatments of 17α-estradiol is in consistency with reduced protection against glutamate-induced cell death.
To further find the mechanism behind the calcium response in neurons pretreated with 17α-estradiol, we examined the expression of the NMDA receptor unit NR2B in the neurons before the cells were exposed to glutamate ( Figure 4E-F) . Cells pretreated with 10 µM 17α-estradiol for 24 h had a significant 7-fold increase in NR2B protein level on DIV4. Thus, NR2B levels may explain the difference in glutamate-induced calcium levels between pretreatment with 1 nM and 10 µM of 17α-estradiol.
Discussion
Non-feminizing estradiol analogs are reported to be equally or more potent than 17β-estradiol against glutamate toxicity [5] . In the present work we demonstrate that 10 uM 17α-estradiol, but not 1 nM, is neuroprotective when administered together with glutamate, most likely because of the lower calcium level. On the other hand, pretreatment with 1 nM 17α-estradiol protects, whereas 10 uM 17α-estradiol fails to provide neuroprotection because of upregulation of NR2B, no decrease in calcium level, and a reduction in GSH levels. Our previous findings in rat and mice CGNs showed that a pretreatment period with 10 µM of 17α-estradiol abolished the acute neuroprotection against glutamate-induced toxicity in CGNs [8] , consistent with our present study in chicken CGNs. Also, these results were linked to reduced GSH levels. The present results suggest that 17α-estradiol acts through different mechanisms with low and high concentration. Since estrogens work as ROS scavengers we confirmed this by investigating the levels of peroxynitrite. NO is enhanced due to NMDA receptor activation of nNOS during glutamate exposure [11] and NO reacts fast with 11 superoxide to form peroxynitrite. All treatments except pretreatment with 10 µM 17α-estradiol reduced the ROS levels after glutamate exposure. This suggests that other mechanisms are involved in the glutamate-induced death since the non-protective acute treatment with 1 nM also reduced the ROS levels. The reduced ROS levels by acute treatment were also accompanied by no reduction in GSH levels. Further, glutamate exposed cells pretreated with 1 nM and 10 µM had similar reduction in GSH levels as glutamate alone. This fails to explain the protective effect of pretreatment with 1 nM. However, pretreatment with 10 µM for 24 h reduced the GSH levels. Pretreatment with 10 µM did not affect the synthesis of the glutamate cysteine ligase catalytic subunit GCLC of the rate limiting enzyme GCL in GSH synthesis (data not shown), suggesting that reduced activity of the enzyme and/or depletion of GSH are responsible for the reduced GSH levels [23] . A sufficient level of the key antioxidant GSH is needed for neuroprotective actions of 17β-estradiol and 17α-estradiol in nM and µM doses [24] . Thus, the neurons are likely to be more vulnerable for an excitotoxic stimulus if GSH levels are decreased at the time point for administration because of reduced capacity to scavenge excess ROS production, and this probably caused the glutamate-induced increase in ROS levels after 1 h with pretreatment 10 µM 17α-estradiol.
To further investigate the non-protective and protective effect of 17α-estradiol against glutamate-induced death we examined glutamate-induced calcium response. Interestingly, only the non-protective treatments gave a significant response in the glutamate-induced calcium levels. Glutamate induces strong calcium signaling through NMDA receptors. Minor changes in intracellular calcium induced by estrogen are linked to biological response [25] , and mirrors neuroprotection in the present work.
Elevated levels of glutamate in the extracellular space and increases in the number of NMDA receptors located extrasynaptically are two pathological states which characterize several neurological diseases [26] . The subunit NR2B is primarily found in extrasynaptic sites [13] .
We therefore examined the expression of NR2B subunit in the CGNs after a pretreatment period with 17α-estradiol. Pretreatment with 10 µM 17α-estradiol enhanced this expression.
Thus, the non-protective effect by pretreatment with 10 µM could be related to increased NR2B levels. Further, delayed neuronal disintegration which occurs hours after glutamate exposure, depends on presence of extracellular calcium [27] , and increased levels of NR2B could amplify this process.
Research suggests that ERs are involved in the neuroprotection of estrogen against glutamateinduced neurotoxicity through attenuation of glutamate-induced calcium overload by modulating NMDA receptors [15] . However, 17α-estradiol has weak estrogen activity and may therefore influence calcium influx during glutamate excitotoxicity through other mechanisms, but its weak estrogenic activity at higher concentrations should be taken into
consideration. An ER-independent neuroprotection of 17α-estradiol against glutamateinduced toxicity in cortical neurons via protein phosphatase preservation and through extracellular signal-regulated kinase 1/2 has also been reported [28] . Thus, further studies will help to understand the mechanisms behind the concentration and time dependent neuroprotection by 17α-estradiol in cerebellar neurons. 
